Lisa M C van Hoogstraten
Overview
Explore the profile of Lisa M C van Hoogstraten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
86
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pijpers O, van Hoogstraten L, Remmers S, Beijert I, Oddens J, Witjes J, et al.
Eur Urol Oncol
. 2024 Sep;
PMID: 39327188
Patients with high-risk non-muscle-invasive bladder cancer (NMIBC) receive bacillus Calmette-Guérin (BCG) instillations to reduce the risk of progression. For patients with very high-risk NMIBC, immediate radical cystectomy may be considered,...
2.
van Hoogstraten L, Witjes J, Ripping T, Nooter R, Kiemeney L, Aben K
Bladder Cancer
. 2024 Jul;
7(2):193-203.
PMID: 38994541
Background: EAU guidelines recommend a single instillation (SI) of intravesical chemotherapy (e.g. Mitomycin C) within 24 hours after transurethral resection of a bladder tumour (TURBT) in patients with low- to...
3.
van Hoogstraten L, Kiemeney L, Meijer R, van Leenders G, Vanneste B, Incrocci L, et al.
Bladder Cancer
. 2024 Jul;
8(2):139-154.
PMID: 38993368
Background: The COVID-19 pandemic has disrupted regular health care with potential consequences for non-COVID diseases like cancer. To ensure continuity of oncological care, guidelines were temporarily adapted. Objective: To evaluate...
4.
Nuijens S, van Osch F, van Hoogstraten L, Witjes J, Aben K, Hermans T
Urol Oncol
. 2024 Jan;
42(4):117.e11-117.e16.
PMID: 38238116
Background: Current muscle-invasive bladder cancer (MIBC) guidelines recommend not delaying radical cystectomy (RC) >3 months after diagnosis as it decreases overall survival (OS). However, literature investigating the impact of delay...
5.
Bruck K, Meijer R, Boormans J, Kiemeney L, Witjes J, van Hoogstraten L, et al.
Int J Radiat Oncol Biol Phys
. 2023 Jul;
118(1):41-49.
PMID: 37517601
Purpose: Although level I evidence is lacking that radical cystectomy (RC) is superior to bladder-preserving therapy (BPT), RC is still advocated as the recommended treatment in patients with nonmetastatic muscle-invasive...
6.
van Hoogstraten L, Man C, Witjes J, Meijer R, Mulder S, Smilde T, et al.
World J Urol
. 2023 May;
41(7):1837-1845.
PMID: 37258902
Purpose: To evaluate guideline adherence and variation in the recommended use of neoadjuvant chemotherapy (NAC) and the effects of this variation on survival in patients with non-metastatic muscle-invasive bladder cancer...
7.
Nuijens S, van Hoogstraten L, Meijer R, Kiemeney L, Aben K, Witjes J
Eur Urol Open Sci
. 2023 May;
51:47-54.
PMID: 37187720
Background: Minimum volume standards (MVS) for hospitals and/or surgeons remain a subject of debate. Opponents of MVS emphasize the possible negative effects of centralization, such as an unwanted incentive to...
8.
van Hoogstraten L, Vrieling A, van der Heijden A, Kogevinas M, Richters A, Kiemeney L
Nat Rev Clin Oncol
. 2023 Mar;
20(5):287-304.
PMID: 36914746
Bladder cancer is among the ten most common cancers globally, causes considerable morbidity and mortality and is, therefore, a substantial burden for health-care systems. The incidence of bladder cancer is...
9.
de Haar-Holleman A, van Hoogstraten L, Hulshof M, Tascilar M, Bruck K, Meijer R, et al.
Radiother Oncol
. 2023 Mar;
183:109584.
PMID: 36863459
Background And Purpose: Oral capecitabine and intravenous 5-fluorouracil (5-FU) are both used as a radiosensitizer in chemoradiotherapy (CRT). A capecitabine-based regimen is more convenient for both patients and healthcare professionals....
10.
van Hoogstraten L, Witjes J, Meijer R, Ripping T, Kiemeney L, Aben K
BJU Int
. 2022 Jan;
130(6):764-775.
PMID: 35064953
Objectives: To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non-metastatic muscle-invasive bladder cancer (MIBC), and to compare survival of untreated vs...